EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial

Maëva Cotinat iD, Isabelle Boquet iD, Moreno Ursino, Cécile Brocard, Elisabeth Jouve, Corinne Alberti, Laurent Bensoussan, Jean-Michel Viton, Frédéric Brocard, Olivier Blin

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0276892 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2023. Verfasst von Maëva Cotinat und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Neurosciences de la Timone (UMR7289), Aix-Marseille Université and CNRS, Marseille, France. Hauptthemen laut MEDLINE: Riluzole, Spinal Cord Injuries. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Assistance Publique – Hôpitaux de Marseille, Programme Hospitalier de Recherche Clinique, Fondation pour la Recherche Medicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity.

Objective

RILUSCI is a phase 1b–2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.

Methods

In this multicenter double-blind trial, adults (aged 18–65 years) suffering from spasticity after SCI (target enrollment: 90 participants) will be randomly assigned to be given either a placebo or a recommended daily oral dose of riluzole for two weeks. The latter dose will be previously determined in phase 1b of the study by performing double-blind dose-finding tests using a Bayesian continuous reassessment method. The primary endpoint of the trial will be an improvement in the Modified Ashworth Score (MAS) or the Numerical Rating Score (NRS) quantifying spasticity. The secondary outcomes will be based on the safety and pharmacokinetics of riluzole as well as its impact on muscle spasms, pain, bladder dysfunction and quality of life. Analyses will be performed before, during and after the treatment and the placebo-controlled period.

Conclusion

To the best of our knowledge, this clinical trial will be the first to document the safety and efficacy of riluzole as a means of reducing spasticity in patients with chronic SCI.

Trial registration

The clinical trial, which is already in progress, was registered on the ClinicalTrials.gov website on August 9, 2016 under the registration number NCT02859792 . Trial sponsor Assistance Publique–Hôpitaux de Marseille.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RiluzoleSpinal Cord InjuriesAdultHumansQuality of LifeBayes TheoremTreatment OutcomeDouble-Blind MethodMuscle SpasticityMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase I as Topic

Substanzen

Riluzole

Autor:innen und Institutionen

  • Institut de Neurosciences de la Timone (UMR7289), Aix-Marseille Université and CNRS, Marseille, France.
  • Department of Physical and Rehabilitation Medicine, Sainte Marguerite University Hospital, APHM, Marseille, France.
  • Unit of Clinical Epidemiology, Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Robert Debré, FCRIN PARTNERS Platform, Université de Paris, Sorbonne Paris-Cité, INSERM U1123 and CIC-EC 1426, Paris…
  • Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université de Paris, F-75006 Paris, France.
  • Inria, Paris, France.
  • Aix Marseille University, APHM, INSERM, Inst Neurosci Syst, UMR1106, Service de Pharmacologie Clinique et Pharmacovigilance, Marseille, France.

ORCID-Profile: Maëva Cotinat, Isabelle Boquet

Förderung

  • Assistance Publique – Hôpitaux de Marseille
  • Programme Hospitalier de Recherche Clinique
  • Fondation pour la Recherche Medicale

Zitieren

APA

Cotinat, M., Boquet, I., Ursino, M., Brocard, C., Jouve, E., Alberti, C., Bensoussan, L., Viton, J. M., Brocard, F., & Blin, O. (2023). Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0276892

Vancouver

Cotinat M, Boquet I, Ursino M, Brocard C, Jouve E, Alberti C, et al. Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0276892

BibTeX
@article{Cotinat2023,
  author = {Cotinat, Maëva and Boquet, Isabelle and Ursino, Moreno and Brocard, Cécile and Jouve, Elisabeth and Alberti, Corinne and Bensoussan, Laurent and Viton, Jean-Michel and Brocard, Frédéric and Blin, Olivier},
  title = {Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0276892}
}
Kostenlos starten →